[ELVN]
Mid
Mid
2026-10-08 20:52:02
Guggenheim reiterates Enliven Therapeutics stock rating on FDA alignment
Mid
2026-10-07 12:18:46
Enliven, FDA agree on phase 3 trial design for relcobatinib for chronic myeloid leukemia
Mid
2026-07-16 02:16:34
Enliven Therapeutics stock hits 52-week high at 52.47 USD